This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyer, J. S. Articles by Lee, J. Y. Search for Related Content PubMed PubMed Citation Articles by Meyer, J. S. Articles by Lee, J. Y.

Relationships of S-Phase Fraction of Breast Carcinoma in Relapse to Duration of Remission, Estrogen Receptor Content, Therapeutic Responsiveness, and Duration of Survival¹

Department of Pathology and Laboratory Medicine, The Jewish Hospital of St. Louis, St. Louis and Department of Pathology, Washington University School of Medicine [J. S. M.], and Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri 63110 [J. Y. L.]

The fractions of tumor cells in S phase (DNA synthesis) were measured by in vitro thymidine labeling and autoradiography in 48 breast carcinomas after relapse. The S-phase fractions (SPF's), expressed as S-phase cells/100 cells, had a lognormal distribution with a geometric mean of 6.5 and a median of 7.4. Paired SPF measurements on the primary and relapsed breast carcinomas of 14 patients showed that the SPF usually increased over time. The SPF after relapse correlated negatively with the interval between primary therapy and relapse and with duration of survival after relapse. Low SPF's were associated with older age, minimal nuclear anaplasia, and estrogen receptor positivity, but SPF was the only variable that could be shown to have independent prognostic significance. Therefore, the prognostic powers of the estrogen receptor status and nuclear grade appear to result from their correlations with the SPF. Either low SPF or presence of estrogen receptor predicted response to hormonal therapy.

¹ Supported by American Cancer Society Grant 4268IM and by a general research supporting grant from the NIH.

² To whom requests for reprints should be addressed, at Department of Pathology, The Jewish Hospital of St. Louis, 216 South Kingshighway, P. O. Box 14109, St. Louis, Mo. 63178.

Received 11/16/79. Accepted 3/ 5/80.

This article has been cited by other articles:

				A. Paradiso, F. Schittulli, G. Cellamare, A. Mangia, F. Marzullo, V. Lorusso, and M. De Lena Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer J. Clin. Oncol., October 1, 2001; 19(19): 3929 - 3937. [Abstract] [Full Text]

				J. A. Foekens, S. Romain, M. P. Look, P.-M. Martin, and J. G. M. Klijn Thymidine Kinase and Thymidylate Synthase in Advanced Breast Cancer: Response to Tamoxifen and Chemotherapy Cancer Res., February 1, 2001; 61(4): 1421 - 1425. [Abstract] [Full Text]

				D. Kiang, M King, H. Zhang, B. Kennedy, and N Wang Cyclic biological expression in mouse mammary tumors Science, April 2, 1982; 216(4541): 68 - 70. [Abstract] [PDF]